Low-density lipoprotein (LDL) apheresis reduces atherogenic and oxidative markers in uremic patients with hyperlipidemia

Chen, Tung-Sheng; Liou, Show Yih; Wu, Hsi Chin; Tsai, Fuu Jen; Tsai, Chang Hai; Huang, Chih Yang; Chang, Ya‐Ling

doi:10.1007/s11255-010-9722-y

Cited by 6 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The impact of eliminating cytokines or chemokines, in particular of inflammatory mediators, is only poorly understood. These topics are, at least if one analyzes the latest publications, currently the subject of the research in apheresis [39,6]. Little is known about the effects of eliminating other nonselective, sometimes not even identified plasma components.…”

Section: Clinical Efficacy Of Ldl Apheresismentioning

confidence: 99%

Role of lipid apheresis in changing times

Schuff‐Werner

Fenger

Kohlschein

2012

Clin Res Cardiol Suppl

View full text Add to dashboard Cite

During the last decades, LDL-apheresis was established as an extracorporeal treatment option for patients with severe heterozygous or homozygous familial hypercholesterolemia (FH) that is resistant to conventional treatment strategies such as diet, drugs, and changes in lifestyle. Nearly half a century ago, the first LDL-apheresis treatment was performed by plasma exchange in a child with homozygous FH.At the beginning of the 1970s, the clinical advantage of regular extracorporeal LDL-elimination was demonstrated in siblings suffering from homozygous FH. These findings encouraged researchers especially from Germany and Japan to develop extracorporeal devices to selectively eliminate LDL-cholesterol in the 1980s.Although the selectivity of the currently available LDL-apheresis devices is different, the efficacy of LDL-elimination during a single treatment is rather similar and ranges between 55 and 65 % of the pretreatment LDL plasma concentration.In the 1990s, the patients regularly treated by extracorporeal LDL-elimination, diet, and drugs were included in regression studies assessed by angiography. It was shown that the combined treatment with LDL-apheresis, diet, and drugs resulted in less progression of coronary lesions than drugs and/or diet alone. However, although a tendency was evident, results did not reach criteria for significance.During the last decade, apheresis registries were established to collect data on efficiency, safety, and clinical outcome of regular long-term LDL-apheresis. The evaluation of registry data will certainly permit further insights in the therapeutic benefit of this expensive and time-consuming therapeutic approach.Furthermore, the future of LDL-apheresis will depend upon the availability of highly efficient new drugs and molecular genetic approaches such as RNA silencing of the apoB gene, whereas the liver transplantation and gene therapy of the LDL-receptor deficiency will not replace LDL-apheresis in severe familial hypercholesterolemia in the near future.

show abstract

Section: Clinical Efficacy Of Ldl Apheresismentioning

confidence: 99%

Role of lipid apheresis in changing times

Schuff‐Werner

Fenger

Kohlschein

2012

Clin Res Cardiol Suppl

View full text Add to dashboard Cite

show abstract

“…LDLs appear to be modified by a process of oxidation in endothelial cells. Extensively oxidized LDL (oxLDL) is exceedingly atherogenic (Chen et al, 2010). Recently, ATP-sensitive potassium channel openers have been shown to enhance NO release, reduce levels of mRNA for endothelin-1, exert antiapoptotic effects, and inhibit the overexpression of adhesion molecules in aortic endothelial cells under metabolic disturbances induced by oxidized low-density lipoprotein (Maurey et al, 2006).…”

Section: Scuss Onmentioning

confidence: 99%

Association of E23K polymorphism of Kir6.2 gene with coronary artery disease

Benlier¹

2011

Afr. J. Pharm. Pharmacol.

View full text Add to dashboard Cite

“…This causative agent is one that, in HD, induces oxidative stress. However, HD is capable of removing uremic solutes, a process that also induces elevation of oxidative stress in uremic patients, resulting in an increase in complications associated with oxidative damage of biomolecules .…”

Section: Introductionmentioning

confidence: 99%

Chemiluminescence analysis of antioxidant capacity for serum albumin isolated from healthy or uremic volunteers

Huang

Liou²,

Kuo

et al. 2016

Luminescence

Self Cite

View full text Add to dashboard Cite

Regular hemodialysis treatment induces an elevation in oxidative stress in patients with end-stage renal failure, resulting in oxidative damage of the most abundant serum protein, albumin. Oxidation of serum albumin causes depletion of albumin reactive thiols, leading to oxidative modification of serum albumin. The aim of this study was to screen the antioxidant capacity of albumins isolated from uremic patients (HD-ALB) or healthy volunteers (N-ALB). From high-performance liquid chromatography spectra, we observed that one uremic solute binds to HD-ALB via the formation of disulfide bonds between HD-ALB and the uremic solute. Furthermore, we found using chemiluminescent analysis that the antioxidant capacities for N-ALB to scavenge reactive oxygen species including singlet oxygen, hypochlorite and hydrogen peroxide were higher than HD-ALB. Our results suggest that protein-bound uremic solute binds to albumin via formation of disulfide bonds, resulting in the depletion of albumin reactive thiols. The depletion of albumin reactive thiols leads to a reduced antioxidant capacity of HD-ALB, implying postmodification of albumin. This situation may reduce the antioxidant capacity of albumin and increase oxidative stress, resulting in increase in complications related to oxidative damage in uremic patients. Copyright © 2016 John Wiley & Sons, Ltd.

show abstract

Low-density lipoprotein (LDL) apheresis reduces atherogenic and oxidative markers in uremic patients with hyperlipidemia

Cited by 6 publications

References 13 publications

Role of lipid apheresis in changing times

Role of lipid apheresis in changing times

Association of E23K polymorphism of Kir6.2 gene with coronary artery disease

Chemiluminescence analysis of antioxidant capacity for serum albumin isolated from healthy or uremic volunteers

Contact Info

Product

Resources

About